Search
netupitant; fosnetupitant
Indications:
- used in combination with palonosetron in the treatment of nausea & vomiting associated with chemotherapy [1]
Dosage:
- fosnetupitant 325 mg
Mechanism of action:
- neurokinin-1 receptor antagonist
General
anti-emetic
receptor antagonist
References
- Calcagnile S1, Lanzarotti C, Rossi G et al
Effect of netupitant, a highly selective NK1 receptor
antagonist, on the pharmacokinetics of palonosetron and impact
of the fixed dose combination of netupitant and palonosetron
when coadministered with ketoconazole, rifampicin, and oral
contraceptives.
Support Care Cancer. 2013 Oct;21(10):2879-87
PMID: 23748441
- Pharmacy News. Oct 14, 2014
Netupitant-Palonosetron Combination Approved by FDA.
http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?id=4118